Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 12/2016

Open Access 01-12-2016 | Review Article

A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration

Authors: Parag Kumar, Emily Thudium, Kevin Laliberte, David Zaccardelli, Andrew Nelsen

Published in: Clinical Pharmacokinetics | Issue 12/2016

Login to get access

Abstract

Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso® (treprostinil sodium, inhaled administration), and Orenitram® (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). Pharmacokinetic studies have been performed in healthy volunteers and patients with PAH. The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH.
Literature
1.
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–619.CrossRefPubMed
2.
Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84(1):68–75.CrossRefPubMed
3.
Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(9):1161–70.CrossRefPubMedPubMedCentral
4.
Patel J, Shen L, Hall S, et al. EP2 receptors play a key role in mediating the anti-proliferative activity of treprostinil in smooth muscle cells derived from the lungs of pulmonary hypertensive patients. Am J Respir Crit Care Med. 2015;191:A5954.
5.
Jing ZC, Parihk K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–33.CrossRefPubMed
6.
Benza RL, Seegar W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transpl. 2011;30(12):1327–33.CrossRef
7.
Simonneau G, Barst R, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:800–4.CrossRefPubMed
8.
Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007;123(3):757–63.CrossRef
9.
Remodulin U.S. package insert. Research Triangle Park: United Therapeutics Corporation; 2014.
10.
Tyvaso U.S. package insert. Research Triangle Park: United Therapeutics Corporation; 2014.
11.
Orenitram U.S. package insert. Research Triangle Park: United Therapeutics Corporation; 2016.
12.
Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil administered to treat pulmonary artery hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trial. Chest. 2016. doi:10.​1016/​j.​chest.​2015.​11.​005.PubMed
13.
Bourge R. Treprostinil administered using a fully implantable programmable intravascular delivery system: results of the Delivery for PAH trial [oral presentation]. American College of Chest Physicians Annual Meeting: Austin; 25–30 Oct 2014.
14.
Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209–14.CrossRefPubMed
15.
Wade M, Maker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004;44(5):503–9.CrossRefPubMed
16.
McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol. 2008;48(1):19–25.CrossRefPubMed
17.
Nelsen AC, Laliberte KJ, Zaccardelli DS, et al. Pharmacokinetics of inhaled treprostinil sodium in healthy volunteers. Am J Respir Crit Care Med. 2010;181:A338.
18.
Bourge RC, Tapson VF, Safdar Z, et al. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2013;31(1):38–44.
19.
White RJ, Torres F, Allen R, et al. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2013;61(6):474–81.CrossRefPubMed
20.
Laliberte K, Goetz B, Phares K, et al. Sustained treprostinil plasma concentrations following administration of UT-15C (treprostinil diethanolamine) sustained release tablets in healthy volunteers [poster]. American Thoracic Society International Conference: San Francisco; 18–23 May 2007.
21.
Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48(7):1433–7.CrossRefPubMed
22.
Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8):1672–81.CrossRefPubMed
23.
White RJ, Frutiger K, Theuer A, et al. A pharmacokinetic and tolerability comparison in subjects transitioning from twice daily to three times daily dosing of oral treprostinil. Chest. 2014;146:865A.CrossRef
24.
White RJ, Jing Z, Parikh K, et al. An open-label extension trial of oral treprostinil in subjects with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187:A3270.CrossRef
25.
Lim A, Wang-Smith L, Kates J, et al. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers. J Clin Pharm Ther. 2013;28(6):450–5.CrossRef
26.
Gotzkowsky SK, Dingemanse J, Lai A, et al. Lack of a pharmacokinetic drug interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010;50(7):829–34.CrossRefPubMed
27.
Gotzkowsky SK, Kumar P, Mottola D, et al. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. J Cardiovasc Pharmacol. 2013;61(5):444–51.CrossRefPubMed
28.
Rollins K, Peterson L, Laliberte K, et al. Overview of the drug-drug interaction potential with treprostinil. Am J Respir Crit Care Med. 2009;197:A3367.
29.
Rollins K, Walker S, Kates BA, et al. The effect of gastric acid suppression with esomeprazole on treprostinil diethanolamine pharmacokinetics in healthy volunteers. Am Coll Rheumatol. 2010;62(10):A597.
30.
Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol. 2003;41(6):908–15.CrossRefPubMed
31.
Rollins K, Laliberte K, Gotzkowsky SK, et al. Overview of the drug-drug interaction potential with treprostinil [abstract no. P3852]. European Respiratory Society 19th Annual Congress: Vienna; 12–15 Sep 2009.
32.
Peterson L, Marbury T, Marier J, et al. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. J Clin Ther. 2013;38(6):518–23.CrossRef
33.
Jenkins A, Wang-Smith L, Marbury T, et al. Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. J Cardiovasc Pharmacol. 2013;61(4):272–6.CrossRefPubMed
34.
White RJ, Frutiger K, Theuer A, et al. A pharmacokinetic and tolerability comparison in subjects transitioning from twice daily to three times daily dosing of oral treprostinil [oral presentation]. American College of Chest Physicians Annual Meeting: Austin; 25–30 Oct 2014.
35.
White RJ, Chakinala M, Mathier M, et al. Safety and tolerability of transitioning from parenteral treprostinil to oral treprostinil in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187:A3303.CrossRef
36.
Sandifer B, Brigham K, Lawrence E, et al. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol. 2005;99:2363–8.CrossRefPubMed
37.
White RJ, Chakinala M, Rischard F, et al. Safety and tolerability of transitioning from parenteral treprostinil to oral treprostinil in patients with pulmonary arterial hypertension [oral presentation]. American Thoracic Society International Conference: San Diego; 18–21 May 2014.
38.
Barst RG, Galie N, Simonneau G, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195–203.CrossRefPubMed
39.
McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–22.CrossRefPubMed
Metadata
Title
A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
Authors
Parag Kumar
Emily Thudium
Kevin Laliberte
David Zaccardelli
Andrew Nelsen
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-016-0409-0

Other articles of this Issue 12/2016

Clinical Pharmacokinetics 12/2016 Go to the issue

Original Research Article

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals

Review Article

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Original Research Article

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole

Acknowledgement to Referees

Acknowledgement to Referees

Original Research Article

Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations

Review Article

Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations